The globalobstructive uropathy treatment market was valued atUS$ 5 Billion in FY 2021, and is forecast to incline at a Y-o-Y valuation of 5.6% to reach a valuation of US$ 5.3 Billion in 2022. During the 2022-2032 forecast period, the market is poised to expand at a 5.2% value CAGR to reach US$ 8.8 Billion.
| Report Attribute | Details |
| Estimated Base Year Value (2021) | US$ 5 Billion |
| Expected Market Value (2022) | US$ 5.3 Billion |
| Anticipated Forecast Value (2032) | US$ 8.8 Billion |
| Projected Growth Rate (2022-2032) | 5.2% CAGR |
Obstructive uropathy is an obstruction and hindrance in the urinal tract that causes complete or partial obstructions to the normal flow of urine. Obstructive uropathy is caused by a structural or functional malfunction that prevents urine drainage and can lead to serious complications if not treated. Obstructive uropathy can be either acute or chronic.
Obstructive uropathy treatment is appropriate for people of all ages because it can affect anyone at any age. Obstructive uropathy accounts for 10% of the causes of acute renal failure and 4% of cases of chronic end-stage renal failure. Obstructive uropathy can be caused by a neoplastic condition, inflammation, or it can be inherited.
Treatment for obstructive uropathy entails inserting catheters or stents into the kidney or ureter to restore normal urine flow. The treatment for obstructive uropathy is minimally invasive and has a high success rate. The nephron-ureterostomy catheter is inserted through the skin and allows urine to flow from the bladder to the renal pelvis.
A ureteral stent is a tube that is implanted in the ureter and allows urine to flow from the kidney to the bladder. Hydronephrosis is a condition in which there is an excess of fluid in the kidney that is treated with obstructive uropathy. Prompt obstruction relief by the obstructive uropathy treatment market usually results in the preservation of kidney function.
The rising prevalence of kidney stones as a result of changing lifestyles is driving the growth of the global obstructive uropathy treatment market. Furthermore, the rising incidence of cancer and postoperative infection in kidney transplant recipients drives the growth of the obstructive uropathy treatment market.
Over the forecast period, the rising prevalence of hydro nephrosis in the population is expected to create a high demand for obstructive uropathy treatment. The increasing number of manufacturers and distributors of catheters and stents for obstructive uropathy treatment is increasing the regional availability of the products in underserved regions and fueling the market for obstructive uropathy treatment.
Because of the increasing adoption of the products by end-users, the global obstructive uropathy treatment market is expected to grow significantly over the forecast period. An autopsy series of 59,064 subjects ranging in age from infants to geriatric people revealed that 3.1 percent were positive for hydronephrosis, and this figure is expected to rise further, propelling demand for the obstructive Uropathy market.
Surgery to remove the obstruction or place a stent can have side effects such as discomfort and an increased risk of infection, which can hamper market growth slightly.
Because of the region's high prevalence of urological disorders and higher healthcare expenditure, North America is expected to be the market leader in global obstructive uropathy treatment. Because of the increasing prevalence of kidney stones in this region, North America is expected to hold a significant market share in the global uropathy treatment market.
According to a study published in the Clinical Journal of the American Society of Nephrology, one in every eleven people in the United States will develop a urinary stone during their lifetime. Furthermore, the prevalence of urinary stone disease in children is increasing year after year, particularly among adolescents. Furthermore, technological advancements and new product launches, as well as the presence of a well-established healthcare infrastructure, are fueling the overall regional market's growth to a large extent.
Due to higher healthcare spending and greater adoption by end-users in the region, the Europe obstructive uropathy treatment market is expected to account for the second-largest share in the obstructive uropathy treatment market over the forecast period. The market for obstructive uropathy treatment is expected to grow at a rapid CAGR over the forecast period, owing to increased manufacturer presence and end-user adoption.
Some of the major players identified in the global obstructive uropathy treatment market are Boston Scientific Corporation, Olympus Corporation, Teleflex Incorporated, B. Braun Melsungen AG, Applied Medical, AngioDynamics, Merit Medical Systems, Inc., Argon Medical Devices, Inc., optimed, Cook Medical, Teleflex Incorporated, B. Braun Melsungen AG, and C. R. Bard amongst others.
| Report Attribute | Details |
| Growth Rate | CAGR of 5.2% from 2022 to 2032 |
| Base Year for Estimation | 2021 |
| Historical Data | 2015-2020 |
| Forecast Period | 2022-2032 |
| Quantitative Units | Revenue in USD Billion, Volume in Kilotons and CAGR from 2022-2032 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
| Segments Covered |
|
| Regions Covered |
|
| Key Countries Profiled |
|
| Key Companies Profiled |
|
| Customization | Available Upon Request |
By Product Type:
By End Users:
By Region:
FMI projects the global Obstructive Uropathy Treatment market to expand at a 5.2% value CAGR by 2032.
North America is expected to be the most opportunistic Obstructive Uropathy Treatment market.
Some of the major players identified in the global obstructive uropathy treatment market are Boston Scientific Corporation, Olympus Corporation, Teleflex Incorporated, B. Braun Melsungen AG, Applied Medical, AngioDynamics, Merit Medical Systems, Inc., Argon Medical Devices.
Explore Similar Insights
Obstructive Uropathy Treatment Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
Chat With
MaRIA
